Reacta appoints Kevin Hawkins as new head of regulatory affairs
Reacta Healthcare, an early-stage food allergy diagnostic company, has announced the appointment of Kevin Hawkins as head of regulatory affairs.
Hawkins has extensive leadership experience including in R&D, regulatory affairs, analytical development and project leadership, having previously worked as senior director and head of development at Teva Pharmaceuticals for more than ten years. He has also worked in regulatory affairs for the last 15 years, building an R&D team at Teva with experience in multiple dosage form areas such as inhalation, ophthalmic, parenteral and nasal sprays.
Dr Paul Abrahams, CEO of Reacta Healthcare, said: “We are delighted to welcome Kevin to the Reacta Senior Leadership Team at this critical juncture in the company’s development. Kevin is a highly skilled and respected senior leader with a strong track record in R&D and Regulatory Affairs. His experience in dealing with regulators and his practical approach to regulatory matters will be a great asset to Reacta and will be invaluable in contributing to the growth of the company.”
Professor Ashley Woodcock, chairman at Reacta, added: “Our ultimate strategic goal is to achieve a Marketing Authorisation for our challenge meal products and Kevin will play an instrumental role in progressing this strategy, particularly given recent positive feedback from several Health Authorities to our product and approach.”
Commenting on his appointment, Hawkins stated: “I am thrilled to be joining Reacta at this critical time as the company progresses its regulatory strategy with Health Authorities globally. I look forward to supporting the Executive Team in their continued efforts to build Reacta as a leading food allergy diagnostics company seeking to improve the lives of food allergy sufferers.”
Pharmaceutical Industry news, analysis and insights